{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:54Z","timestamp":1792715874307,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108366","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:56:22Z","timestamp":1791507382000},"page":"108366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-line toripalimab in combination with platinum-doublet chemotherapy for advanced B3 thymoma and thymic carcinoma: an open-label prospective phase \u2161 trial"],"prefix":"10.1016","volume":"11","author":[{"given":"K.","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6652-2384","authenticated-orcid":false,"given":"X.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2026.108366_bib1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2026.108366_bib2","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108366_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/annonc\/mdu541","article-title":"A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L","volume":"26","author":"Hirai","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108366_bib4","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108366_bib5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108366_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108366_bib7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108366_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108366_bib9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108366_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108366_bib11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s12094-024-03618-x","article-title":"The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumors","volume":"27","author":"Si","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.esmoop.2026.108366_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2022.06.059","article-title":"Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: a multicentre retrospective study","volume":"174","author":"Wang","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108366_bib63","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108366_bib54","doi-asserted-by":"crossref","first-page":"101921","DOI":"10.1016\/j.tranon.2024.101921","article-title":"Comprehensive genomic and clinical analyses identify APOBEC mutational signatures as a brain metastasis risk factor in lung adenocarcinoma patients","volume":"43","author":"Li","year":"2024","journal-title":"Transl Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2026.108366_bib52","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108366_bib53","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1038\/nprot.2016.150","article-title":"Indel variant analysis of short-read sequencing data with Scalpel","volume":"11","author":"Fang","year":"2016","journal-title":"Nat Protoc"},{"key":"10.1016\/j.esmoop.2026.108366_bib55","first-page":"68","article-title":"The 1000 Genomes Project Consortium. A global reference for human genetic variation","volume":"526","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2026.108366_bib56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.esmoop.2026.108366_bib57","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"18","key":"10.1016\/j.esmoop.2026.108366_bib58","doi-asserted-by":"crossref","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","article-title":"DELLY: structural variant discovery by integrated paired-end and split-read analysis","volume":"28","author":"Rausch","year":"2012","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108366_bib59","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"2\u20133","key":"10.1016\/j.esmoop.2026.108366_bib60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12026-014-8516-1","article-title":"ImmPort: disseminating data to the public for the future of immunology","volume":"58","author":"Bhattacharya","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.esmoop.2026.108366_bib61","unstructured":"Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using \u2018ggplot2\u2019[CP]. R package version 0.5.2. Available at https:\/\/github.com\/kassambara\/survminer. Accessed February 1, 2025."},{"issue":"7","key":"10.1016\/j.esmoop.2026.108366_bib62","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/ijc.70561","article-title":"The 9th edition of the UICC TNM classification of malignant tumours: updates and rationale for change","volume":"159","author":"Brierley","year":"2026","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108366_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"24","key":"10.1016\/j.esmoop.2026.108366_bib14","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108366_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108366_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard","year":"2023","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108366_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108366_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(25)00001-4","article-title":"Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial","volume":"26","author":"Shukuya","year":"2025","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108366_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2026.108366_bib20","article-title":"Expression of PD-L1, PD-L2 and PD-1 in thymic epithelial tumours (TETs)","volume":"34","author":"Gennatas","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108366_bib21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.annonc.2024.06.002","article-title":"Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)","volume":"35","author":"Proto","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108366_bib22","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","article-title":"Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Conforti","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108366_bib23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S1470-2045(25)00300-6","article-title":"Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial","volume":"26","author":"Remon","year":"2025","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2026.108366_bib24","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"issue":"50","key":"10.1016\/j.esmoop.2026.108366_bib25","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1038\/onc.2010.378","article-title":"An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells","volume":"29","author":"Alameda","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2026.108366_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.lungcan.2020.07.018","article-title":"Downregulation of CYLD promotes IFN-\u03b3 mediated PD-L1 expression in thymic epithelial tumors","volume":"147","author":"Umemura","year":"2020","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108366_bib27","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/cdd.2017.46","article-title":"CYLD, A20 and OTULIN deubiquitinases in NF-\u03baB signaling and cell death: so similar, yet so different","volume":"24","author":"Lork","year":"2017","journal-title":"Cell Death Differ"},{"issue":"6950","key":"10.1016\/j.esmoop.2026.108366_bib28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nature01803","article-title":"CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members","volume":"424","author":"Trompouki","year":"2003","journal-title":"Nature"},{"issue":"6950","key":"10.1016\/j.esmoop.2026.108366_bib29","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature01802","article-title":"The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination","volume":"424","author":"Kovalenko","year":"2003","journal-title":"Nature"},{"issue":"5103","key":"10.1016\/j.esmoop.2026.108366_bib30","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.8096091","article-title":"NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway","volume":"259","author":"Sun","year":"1993","journal-title":"Science"},{"issue":"4878","key":"10.1016\/j.esmoop.2026.108366_bib31","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1126\/science.3140380","article-title":"I kappa B: a specific inhibitor of the NF-kappa B transcription factor","volume":"242","author":"Baeuerle","year":"1988","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108366_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"594","key":"10.1016\/j.esmoop.2026.108366_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf5058","article-title":"cIAP1\/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes","volume":"13","author":"Roehle","year":"2021","journal-title":"Sci Transl Med"},{"issue":"19","key":"10.1016\/j.esmoop.2026.108366_bib34","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1158\/0008-5472.CAN-22-0018","article-title":"Targeting Plk1 sensitizes pancreatic cancer to immune checkpoint therapy","volume":"82","author":"Zhang","year":"2022","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108366_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccell.2025.01.008","article-title":"Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases","volume":"43","author":"Rodriguez-Baena","year":"2025","journal-title":"Cancer Cell"},{"issue":"36","key":"10.1016\/j.esmoop.2026.108366_bib36","article-title":"SHISA3 reprograms tumor-associated macrophages toward an antitumoral phenotype and enhances cancer immunotherapy","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.esmoop.2026.108366_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122424","article-title":"Glucosylation endows nanoparticles with TLR4 agonist capability to trigger macrophage polarization and augment antitumor immunity","volume":"304","author":"Liu","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.esmoop.2026.108366_bib38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","article-title":"PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus","volume":"60","author":"Marchevsky","year":"2017","journal-title":"Hum Pathol"},{"issue":"14","key":"10.1016\/j.esmoop.2026.108366_bib39","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.3390\/ijms23147864","article-title":"Unraveling the immune microenvironment of thymic epithelial tumors: implications for autoimmunity and treatment","volume":"23","author":"Masaoutis","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2026.108366_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108366_bib41","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1172\/JCI90387","article-title":"CD56bright NK cells exhibit potent antitumor responses following IL-15 priming","volume":"127","author":"Wagner","year":"2017","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108366_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100930","article-title":"NK cell infiltration is associated with improved overall survival in solid cancers: a systematic review and meta-analysis","volume":"14","author":"Nersesian","year":"2021","journal-title":"Transl Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108366_bib43","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/jcmm.12109","article-title":"The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients","volume":"17","author":"Pantano","year":"2013","journal-title":"J Cell Mol Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108366_bib44","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.946818","article-title":"M1 and M2: there is no \u201cgood\u201d and \u201cbad\u201d-How macrophages promote malignancy-associated features in tumorigenesis","volume":"3","author":"Helm","year":"2014","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108366_bib45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","article-title":"Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications","volume":"12","author":"Lin","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108366_bib46","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108366_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct Target Ther"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926023094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926023094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:41:51Z","timestamp":1792712511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926023094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2059702926023094"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108366","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line toripalimab in combination with platinum-doublet chemotherapy for advanced B3 thymoma and thymic carcinoma: an open-label prospective phase \u2161 trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108366"}}